Showing 1971-1980 of 5808 results for "".
Treatment of Psychodermatological Conditions Using N-acetylcysteine
https://practicaldermatology.com/columns/physician-spotlight/treatment-of-psychodermatological-conditions-using-n-acetylcysteine/23998/The low risk, high reward of NAC suggests its great promise in a supplementary role for treatment of trichotillomania and excoriation disorder.How To Influence Others, Dermatology Practice-Style
https://practicaldermatology.com/topics/practice-management/how-to-influence-others-dermatology-practice-style/23963/Influence means “to have an effect on the behavior of someone or something.”Pharma Sales 2.0
https://practicaldermatology.com/topics/practice-management/pharma-sales-20/23959/A behind-the-scenes look at how ReachRX aims to transform pharma sales and boost patient access.Physician Spotlight With Latanya Benjamin, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-with-latanya-benjamin-md/23950/Physician Spotlight: Meena Singh, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-meena-singh/23939/Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eDermWireTV: Updates from ASDS: EBDs, Injectables, Scars, DEI
https://practicaldermatology.com/topics/practice-management/dermwiretv-updates-from-asds-ebds-injectables-scars-dei/20029/The annual meeting of the American Society for Dermatology Surgery (ASDS) brings together top dermatologists to share their expertise. This year’s virtual meeting offered a look at a range of new and emerging treatments and some updates on existing options, including insights from Jeanine B. Downie,Muscle Makers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/muscle-makers/23541/The newest body sculpting technologies show promise for building muscle and strength.Rosacea Update: A Closer Look at Zilxi
https://practicaldermatology.com/columns/clinical-focus-1/rosacea-update-a-closer-look-at-zilxi/23339/Inside the approval of Zilxi for moderate-to-severe facial papulopustular rosacea.